News and Insights

Pharmaceuticals and Medical Devices

Optimizing Global Launch Sequencing

Traditionally, launch sequencing has been guided by market size, eligible patient population, and the likelihood of securing market access and adoption. While these criteria are still important, they’re no longer sufficient. Growing budget constraints, more stringent evidence requirements, and the rise of external reference pricing and transparency are forcing pharma…

Prioritizing Evidence Generation For Impact

Across the globe, pharma companies are encountering new levels of price resistance and competitive pressure.  Providing compelling evidence to demonstrate differentiated value has been recognized as key to mitigating these pressures.  However, restrictive regulations threaten to significantly change the financial picture across the industry, such that no functional area will…

Establishing a Research Network to Drive Differentiation in a Dynamic Market

Clinical research networks continue to play a pivotal role in supporting pipeline development.  However, the importance of these networks extends well beyond the conduct of clinical trials.  Clinical investigators can support market conditioning, serve as important levers for informing evidence-based clinical pathways/guidelines, and aid in the generation of real-world evidence…

The Future of Medical Affairs: Impact of the Evolving Healthcare Landscape

The pandemic has dramatically accelerated many changes across healthcare, and one of them is redefinition of Medical Affairs’ role in commercialization. The shift to virtual detailing and the increased focus on economic and clinical value have implications for Medical Affairs well beyond staffing numbers. These changes demand that Medical Affairs…